-transparent.png){kind=logo}
Several different laboratories have provided sufficient information to establish platelet-activating factor, or AGEPC, as one of the most potent lipid chemical mediators known to date and one with a particularly broad spectrum of biological activities. The data presented in this chapter strengthen this generalization and show yet another dramatic biochemical effect of this unusual phosphoglyceride. The mechanism by which AGEPC effects glycogenolysis and vasoconstriction remains the subject of an ongoing investigation.
Related Publications
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
January 1983,
Seikagaku. The Journal of Japanese Biochemical Society,
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
July 1995,
Journal of internal medicine,
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
November 2022,
BioFactors (Oxford, England),
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
January 1987,
Advances in prostaglandin, thromboxane, and leukotriene research,
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
January 1990,
Cerebrovascular and brain metabolism reviews,
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
November 1988,
Hospital practice (Office ed.),
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
November 2003,
The Journal of physiology,
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
May 1988,
The Journal of allergy and clinical immunology,
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
January 1992,
Current topics in cellular regulation,
D J Hanahan, and
D Buxton, and
O Halvorsen, and
M S Olson
February 1985,
European journal of pharmacology,
